← Eichor
Study identifier: NCT05281471 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Condition: Platinum-resistant Ovarian Cancer · Platinum-refractory Ovarian Cancer · Fallopian Tube Cancer  ·  Sponsor: Genelux Corporation

PhasePhase 3
Planned participants186
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (32)

The University of South Alabama, Mitchell Cancer InstituteMobile, Alabama, United StatesRecruiting
University of Arizona Cancer CenterTucson, Arizona, United StatesRecruiting
City of HopeDuarte, California, United StatesRecruiting
UC San Diego Health - Moores Cancer CenterLa Jolla, California, United StatesRecruiting
Hoag Gynecologic OncologyNewport Beach, California, United StatesRecruiting
UCI Health Chao Family Comprehensive Cancer CenterOrange, California, United StatesRecruiting
AdventHealth Cancer InstituteOrlando, Florida, United StatesRecruiting
Sarasota Memorial Healthcare SystemSarasota, Florida, United StatesRecruiting
Women's Cancer Associates with Women's Care FloridaSt. Petersburg, Florida, United StatesRecruiting
Emory UniversityAtlanta, Georgia, United StatesRecruiting
Indiana University Simon Comprehensive Cancer CenterIndianapolis, Indiana, United StatesRecruiting
Holy Cross HospitalSilver Spring, Maryland, United StatesRecruiting

+ 20 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05281471